GRAIL (NASDAQ:GRAL) Stock: Insider Aaron Freidin Sells 4,100 Shares

Posted by Francis Steltz on Sep 25th, 2026

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 4,100 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total value of $382,694.00. Following the transaction, the chief financial officer directly owned 248,983 shares in the company, valued at approximately $23,240,073.22. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Freidin also recently made the following trade(s):

On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total value of $671,579.00.

GRAIL Stock Up 15.4%

Shares of GRAL opened at $125.21 on Friday. The company has a market cap of $5.59 billion, a PE ratio of -12.84 and a beta of 3.25. The business has a fifty day moving average of $77.33 and a 200 day moving average of $65.25. GRAIL, Inc. has a 52-week low of $41.50 and a 52-week high of $126.81.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. As a group, research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GRAIL

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after acquiring an additional 608,539 shares in the last quarter. Baker BROS. Advisors LP raised its stake in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares in the last quarter. State Street Corp boosted its holdings in shares of GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after purchasing an additional 493,621 shares during the period. Primecap Management Co. CA purchased a new stake in shares of GRAIL in the second quarter valued at approximately $148,836,000. Finally, Geode Capital Management LLC boosted its holdings in shares of GRAIL by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 801,503 shares of the company’s stock valued at $68,609,000 after purchasing an additional 71,253 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GRAL. The Goldman Sachs Group began coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. UBS Group set a $84.00 target price on GRAIL in a research note on Thursday, September 17th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Royal Bank Of Canada started coverage on GRAIL in a research note on Thursday, September 17th. They set a “sector perform” rating and a $84.00 price target for the company. Finally, TD Cowen restated a “buy” rating on shares of GRAIL in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $75.10.

View Our Latest Report on GRAIL

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly supported the evidence for its effectiveness. The vote represents important regulatory progress for GRAIL and its primary commercial product. FDA advisers back safety of Grail’s cancer test, narrowly endorses efficacy
Positive Sentiment: The recommendation moves Galleri closer to final FDA review. Approval could significantly expand GRAIL’s addressable market, strengthen confidence in its technology and support additional adoption of the prescription test. Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote
Positive Sentiment: GRAIL also reported PATHFINDER 2 study findings, providing additional clinical data as investors evaluate Galleri’s effectiveness and commercial potential ahead of the FDA decision. GRAIL Reports PATHFINDER 2 Study Findings
Positive Sentiment: Robert W. Baird raised its price target to $118 from $96 and maintained an “outperform” rating, reflecting greater optimism about Galleri’s regulatory outlook.
Neutral Sentiment: Trading was temporarily halted ahead of the FDA meeting because of pending news, underscoring the event’s significance and contributing to unusually high volatility. Grail Trading Halted Ahead of FDA AdCom Meeting
Neutral Sentiment: A report lists short interest at zero shares, implying no measurable short-selling pressure; however, the figure may reflect a reporting anomaly and should be interpreted cautiously.
Negative Sentiment: The committee’s support for efficacy was narrow, leaving meaningful regulatory uncertainty before the FDA issues its final decision. Goldman Sachs has a “hold” rating, signaling caution after the rally. GRAIL Gets a Hold from Goldman Sachs
Negative Sentiment: CEO Joshua Ofman and CFO Aaron Freidin sold shares under pre-arranged Rule 10b5-1 plans. The transactions were scheduled and leave both executives with substantial holdings, but may still weigh modestly on sentiment.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.